DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Cediranib is an investigational drug.
There have been 100 clinical trials for Cediranib. The most recent clinical trial was a Phase 3 trial, which was initiated on June 15th 2018.
The most common disease conditions in clinical trials are Ovarian Neoplasms, Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), AstraZeneca, and NCIC Clinical Trials Group.
Recent Clinical Trials for Cediranib
|Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma||MFAR||Phase 2|
|Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma||Grupo Español Multidisciplinar de Melanoma||Phase 2|
|Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer||National Cancer Institute (NCI)||Phase 2|